Abivax SA
ABVX
ISIN FR0012333284 / Valor 28479075
Abivax SA
UMushroom community rating:
About company
Abivax SA is a clinical-stage biotechnology company dedicated to the development of therapeutics aimed at modulating the body's natural regulatory mechanisms to manage chronic inflammatory diseases. The company's research and development efforts are centered on creating innovative treatments that can stabilize the immune response, potentially offering new solutions for conditions that currently have limited therapeutic options. By leveraging advanced biotechnological approaches, Abivax aims to address significant unmet medical needs in the field of immunology.
Summarized from source with an LLMView SourceSector: TechnologyLatest Results (17.10.2025):
Abivax SA has announced its financial results for the first half of 2025.
First Half 2025 Financial Results
Abivax SA presented its financial performance for the first half of 2025, as detailed in the company's report.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
7873 M
Market cap (USD)
201,866
Daily traded volume (Shares)
6.99 / 6.7
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
